ALMS

Analyst Note: Alumis Inc. (ALMS)

Date: 2026-06-13 Price: $23.41

1. Structural Readiness

• Conservative Entry: Not yet triggered (awaiting confirmed breakout close).
• Breakout Level: Not yet established in the provided text; requires price action above the current consolidation ceiling.
• Current Price: $23.41.
• Extension: Not applicable (price is within the forming range, not extended above a breakout).

2. Thesis Layer

• Primary Secular Thesis: Biotech & GLP-1 → Immunology & Inflammation.
• Directness: Tier Direct / High Confidence.
• Exposure: Alumis is a direct beneficiary of the secular shift toward targeted immunomodulation, specifically within the TYK2 inhibitor class. The company's core asset, Envu, targets the same pathway validated by the loss-of-function mutation data (P1104A) and the broader market success of TYK2 inhibitors in autoimmune diseases.
• Additional Themes: While the primary focus is Immunology, the pipeline includes A-005 (CNS penetrant TYK2 inhibitor), which touches the Neuroinflammation/Neurodegeneration secular theme. However, the immediate conviction driver is the Psoriasis (PsO) and SLE pipeline.

3. Business Overview

• Company Role: Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune conditions, specifically leveraging the TYK2 pathway.
• Business Model: The company operates on a "clinical-stage biopharma" model, relying on external capital (post-merger) to fund R&D and clinical trials, with the intent to commercialize assets or license them upon regulatory approval.
• Key Assets & Status (as of 2026-06-13):
• Envu (ESK-001): A second-generation TYK2 inhibitor.
• Psoriasis (PsO): The company announced positive topline results for the pivotal Phase 3 ONWARD1 and ONWARD2 trials in Q1 2026. Management has stated a plan to submit a New Drug Application (NDA) to the FDA in the second half of 2026.
• Systemic Lupus Erythematosus (SLE): Envu is currently in a Phase 2 trial, with topline results expected in Q3 2026.
• Long-term Data: Envu is also being evaluated in Phase 2 open-label extension and Phase 3 long-term extension trials.
• A-005: A CNS-penetrant allosteric TYK2 inhibitor. Phase 1 initiation occurred in April 2024, with initial results reported in December 2024.
• Lonigutamab: An IGF-1R monoclonal antibody acquired via the Acelyrin merger. In May 2026, management completed a strategic review and decided to explore strategic alternatives for this program, indicating a potential divestiture or partnership rather than immediate internal commercialization.
• Financial Context: The company is pre-revenue (clinical stage). Forward consensus EPS for FY1 is projected at -$2.86 and FY2 at -$2.73, reflecting continued burn rate typical of late-stage clinical biotechs.

4. Archetype and Conviction

• Archetype: Growth Leader (Clinical Catalyst).
• Fit: The company fits the "Growth Leader" archetype not through current earnings, but through the high-probability structural implication of a near-term regulatory catalyst (NDA submission). The "Growth" is binary and event-driven: the successful submission and subsequent approval of Envu for Psoriasis.
• Valuation & Conviction Stack:
• Thesis Strength: High. The TYK2 mechanism is validated, and the Phase 3 data is positive. The NDA timeline is specific (H2 2026).
• Evidence Quality: Strong. Multiple primary filings (E1, E2, E9, E10) corroborate the positive Phase 3 results and the NDA timeline.
• Rerating Potential: High. The market typically re-rates clinical-stage biotechs significantly upon NDA acceptance and approval. The current price ($23.41) may be pricing in some of the Phase 3 success, but the NDA submission in H2 2026 remains a key catalyst.
• Conviction: The setup is a partial buy signal. The "Forming" state requires a breakout confirmation to be treated as a "Confirmed" setup. The high volatility (ATR 6.5%) necessitates careful position sizing.

5. Invalidations, Strengtheners, and Gaps

• Strengtheners: A confirmed breakout above the current consolidation range (price action confirming the "breakout" state). Positive data readouts from the SLE Phase 2 trial (expected Q3 2026) or the CNS program would add secondary catalysts.
• Gaps in Evidence:
• Specific NDA Submission Date: While "H2 2026" is stated, the exact month is not provided in the evidence.
• Cash Runway: The financial spine shows negative EPS, but specific cash-on-hand or burn rate details (to determine how long they can operate until the NDA approval) are not explicitly detailed in the provided evidence block.
• Lonigutamab Outcome: The decision to "explore strategic alternatives" is noted, but the specific outcome (sale, license, termination) is not yet known.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Positive topline results from Phase 3 ONWARD1 and ONWARD2 trials for Envu in Psoriasis; Management confirmed plan to submit NDA in second half of 2026; TYK2 mechanism validated by loss-of-function mutation data. Key risks: Very high volatility (6.5% ATR) increases risk of false breakouts or sharp invalidation; Clinical stage company with negative EPS and no revenue; Lonigutamab program under strategic review creates uncertainty; FDA approval timeline and potential for additional data requests. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" state and elevated ATR; treat as a partial position until breakout confirmation. Expected path: Price likely consolidates or drifts as the market digests the Q1 2026 data, with a potential volatility spike as the H2 2026 NDA submission date approaches; if the NDA is accepted, the setup may transition from "forming" to "confirmed." Expected horizon: 3 to 6 months (leading up to the H2 2026 NDA submission).